Madrigal Pharmaceuticals (NASDAQ:MDGL) was upgraded by equities research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Saturday.
Other analysts have also recently issued research reports about the company. Evercore ISI raised their target price on Madrigal Pharmaceuticals from $65.00 to $140.00 and gave the stock an “outperform” rating in a research report on Thursday, December 7th. HC Wainwright raised their target price on Madrigal Pharmaceuticals from $54.00 to $105.00 and gave the stock a “buy” rating in a research report on Wednesday, December 6th. Roth Capital began coverage on Madrigal Pharmaceuticals in a research report on Thursday, October 19th. They issued a “buy” rating and a $62.00 target price for the company. JMP Securities raised their target price on Madrigal Pharmaceuticals from $63.00 to $125.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 6th. Finally, Zacks Investment Research cut Madrigal Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, January 9th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Madrigal Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $129.00.
Shares of Madrigal Pharmaceuticals (NASDAQ MDGL) opened at $124.59 on Friday. The firm has a market capitalization of $1,740.00, a price-to-earnings ratio of -50.65 and a beta of 0.80. Madrigal Pharmaceuticals has a one year low of $13.09 and a one year high of $127.80.
Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.11. sell-side analysts anticipate that Madrigal Pharmaceuticals will post -2.57 EPS for the current year.
Several institutional investors have recently modified their holdings of the company. VHCP Management II LLC acquired a new stake in shares of Madrigal Pharmaceuticals in the third quarter worth $1,349,000. JPMorgan Chase & Co. acquired a new stake in shares of Madrigal Pharmaceuticals in the third quarter worth $325,000. SG Americas Securities LLC purchased a new stake in shares of Madrigal Pharmaceuticals during the third quarter worth $100,000. Cambridge Investment Research Advisors Inc. purchased a new stake in shares of Madrigal Pharmaceuticals during the third quarter worth $353,000. Finally, Bank of New York Mellon Corp raised its holdings in shares of Madrigal Pharmaceuticals by 17.9% during the third quarter. Bank of New York Mellon Corp now owns 12,945 shares of the biopharmaceutical company’s stock worth $582,000 after acquiring an additional 1,963 shares in the last quarter. 19.10% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.dispatchtribunal.com/2018/01/20/madrigal-pharmaceuticals-mdgl-rating-increased-to-strong-buy-at-bidaskclub.html.
Madrigal Pharmaceuticals Company Profile
Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.